July 2023 to June 2024
- Yazid Khalil Mo Ghanem, MD (General surgery resident)
- Novel Epigenetic Therapy With Romidepsin And Mithramycin As Intraperitoneal Chemotherapy Perfusion Agents For Peritoneal Colorectal Cancer:
Abstract selected for a Quick Shot Presentation at the ACS Clinical Congress, October 19-22, 2024, San Francisco, CA.
- Promising Potential for Mithramycin A, a novel epigenetic antineoplastic agent, in cytoreductive surgery for peritoneal colorectal cancer:
Abstract (one of only 24) accepted for presentation at the 39th Annual SSAT Residents and Fellows Research Conference, May 18-21, 2024, Washington, DC. Abstract presented at the Plenary Session and at an SSAT Annual Meeting scientific session.
- Improving the Readability of Patient Education Materials About the Whipple Procedure Using Artificial Intelligence, Ghanem YK, Rouhi AD, et al. Accepted for a Mini Oral Presentation at AHPBA 2024, April 4-7, 2024, Miami, FL.
- Use of Novel Epigenetic Therapy Agent Romidepsin in Cytoreductive Surgery for Peritoneal Colorectal Cancer, Ghanem YK et al. Accepted for an ePoster at the Society of Surgical Oncology (SSO) 2024, March 20-23, 2024, Atlanta, GA.
- Novel Epigenetic Therapy With Romidepsin And Mithramycin As Intraperitoneal Chemotherapy Perfusion Agents For Peritoneal Colorectal Cancer:
- Hansa Joshi, MD (General surgery resident)
- Transformation From Lung Adenocarcinoma To Squamous Cell Carcinoma: Drug Resistance And The Role Of Nrf2:
Abstract selected for a full oral presentation at the ACS Clinical Congress, October 19-22, 2024, San Francisco, CA.
- Transformation in non-small cell lung cancer subtypes: Drug resistance and the role of NRF2, Poster, Joshi, Hansa
2nd place winner at the Camden Scholars' Forum 2024, May 2, 2024
- Transformation From Lung Adenocarcinoma To Squamous Cell Carcinoma: Drug Resistance And The Role Of Nrf2:
- Matthew Moccia, MD (General surgery resident)
- Development Of A Bioluminescent Murine Neuroendocrine Tumor Cell Line For The Study Of Epigenetic And Immunologic Treatments In Pancreatic Neuroendocrine Tumors:
Abstract selected for a Full Oral Presentation at the ACS Clinical Congress, October 19-22, 2024, San Francisco, CA.
- Clinicopathologic Trends In Adrenocortical Carcinoma Over A Recent Decade:
Abstract selected for an in-person e-poster presentation at the ACS Clinical Congress, October 19-22, 2024, San Francisco, CA.
- Zena Saleh, Matthew C. Moccia, Zachary Ladd, Upasana Joneja, Yahui Li, Francis Spitz, Young Ki Hong, and Tao Gao. Pancreatic Neuroendocrine Tumors: Signaling Pathways and Epigenetic Regulation. Int. J. Mol. Sci. 2024, 25, 1331. https://doi.org/10.3390/ijms25021331.
- DNA-hypomethylating agent decitabine combined with captem chemotherapy induces reactivation of tumor suppressor genes via downregulation of dnmt1 expression in stc-1 neuroendocrine tumor cells, Poster, Moccia, Matthew
3rd place winner at the Camden Scholars' Forum 2024, May 2, 2024
- Development Of A Bioluminescent Murine Neuroendocrine Tumor Cell Line For The Study Of Epigenetic And Immunologic Treatments In Pancreatic Neuroendocrine Tumors:
- Zena Saleh, MD (General surgery resident)
- Interplay Between Epigenetics And Immune Modulation In Pancreatic Neuroendocrine Tumor (pnet):
Abstract selected for a Quick Shot Presentation at the ACS Clinical Congress, October 19-22, 2024, San Francisco, CA.
- Treatment Patterns For Pancreatic Cancer In Octogenarians: A National Cancer Database (NCDB) Study:
Abstract selected for an in-person e-poster presentation at the ACS Clinical Congress, October 19-22, 2024, San Francisco, CA.
- Zena Saleh, Matthew C. Moccia, Zachary Ladd, Upasana Joneja, Yahui Li, Francis Spitz, Young Ki Hong, and Tao Gao. Pancreatic Neuroendocrine Tumors: Signaling Pathways and Epigenetic Regulation. Int. J. Mol. Sci. 2024, 25, 1331. https://doi.org/10.3390/ijms25021331.
- Interplay Between Epigenetics And Immune Modulation In Pancreatic Neuroendocrine Tumor (pnet):
- Helen Toma, MD (GynOnc fellow)
-
Chemoresistance in high grade serous ovarian cancer molecular subtypes and the role of NRF2, Helen Toma. Abstract accepted for online publication at the American Society of Clinical Oncology Annual Meeting 2024, posted at 5:00 p.m. on May 23, 2024. Abstract Number for Publication: e17574
-
- Zachary Ladd, MS (M2 student)
- Triamterene and Asinex 1 inhibit NRF2 expression in NRF2MUT esophageal squamous cell carcinoma. Abstract selected by the SSAT Scientific Program Committee for a Quick Shot Lecture, Digestive Disease Week 2024, May 18-21, 2024, Washington, DC.
- Zena Saleh, Matthew C. Moccia, Zachary Ladd, Upasana Joneja, Yahui Li, Francis Spitz, Young Ki Hong, and Tao Gao. Pancreatic Neuroendocrine Tumors: Signaling Pathways and Epigenetic Regulation. Int. J. Mol. Sci. 2024, 25, 1331. https://doi.org/10.3390/ijms25021331.
- Marchuk H, Wang Y, Ladd ZA, Chen X, Zhang GF. Pathophysiological mechanisms of complications associated with propionic acidemia. Pharmacol Ther. 2023 Sep;249:108501.
- Triamterene and Asinex 1 inhibit NRF2 expression in NRF2MUT esophageal squamous cell carcinoma. Abstract selected by the SSAT Scientific Program Committee for a Quick Shot Lecture, Digestive Disease Week 2024, May 18-21, 2024, Washington, DC.
July 2022 to June 2023
- Olivia Coburn-Flynn, MD (General Surgery resident)
- Kristen Knapp, MD (General Surgery resident)
- Vincent Verchio, MD (General Surgery resident)
- Knapp K, Verchio V, Coburn-Flynn O, Li Y, Xiong Z, Morrison JC, Shersher DD, Spitz F, Chen X. Exploring cell competition for the prevention and therapy of esophageal squamous cell carcinoma. Biochem Pharmacol. 2023 Aug;214:115639.
- Rebecca Kelly, MD (GynOnc fellow)
- Kelly R, Aviles D, Krisulevicz C, Hunter K, Krill L, Warshal D, Ostrovsky O. The Effects of Natural Epigenetic Therapies in 3D Ovarian Cancer and Patient-Derived Tumor Explants: New Avenues in Regulating the Cancer Secretome. Biomolecules. 2023 Jul 1;13(7):1066.
- Zachary Ladd, BS (M1 student)
- Arnold Rojas, BS (M1 student)